Country: Japan
Language: English
Source: すりの適正使用協議会 RAD-AR Council, Japan
Metreleptin (genetical recombination)
Shionogi & Co., Ltd.
Metreleptin (genetical recombination)
white and clumped injectable preparation
Drug Information Sheet("Kusuri-no-Shiori") Self-injection Published: 07/2013 The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. BRAND NAME: METRELEPTIN FOR SUBCUTANEOUS INJECTION 11.25MG [SHIONOGI] ACTIVE INGREDIENT: Metreleptin (genetical recombination) DOSAGE FORM: white and clumped injectable preparation IMPRINT OR PRINT ON WRAPPING: EFFECTS OF THIS MEDICINE Leptin is one of the hormones secreted from fatty tissues, and it shows an inhibitory effect on food intake and enhancing effect on energy comsumption and on sensitivity of insulin. This medicine enhances sugar and/or lipid metabolism by covering the action of leptin. It is usually used for the treatment of lipodystropy. THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS MEDICINE.BE SURE TO TELL YOUR DOCTOR AND PHARMACIST. ・If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines or foods. ・If you are pregnant or breastfeeding. ・If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.) DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE) ・ Your dosing schedule prescribed by your doctor is(( to be written by a healthcare professional )) ・This medicine can be used after dissolving in water for injection. In general, 0.04 mg as the active ingredient per 1 kg of body weight for male, 0.06 mg for female aged under 18 years old, or 0.08 mg for female aged 18 years old or more is administered by a subcutaneous injection once daily. The initial dose is 0.02 mg, 0.03 mg or Read the complete document